The BCL-2 promoter (-938C>A) polymorphism does not predict clinical outcome in chronic lymphocytic leukemia

Leukemia

Volumn 22, Issue 2, 2008, Pages 339-343

  Kaderi, M A ^a   Norberg, M ^a   Murray, F ^a   Merup, M ^b   Sundstrom C ^a   Roos, G ^c   Aleskog A ^a   Karlsson, K ^d   Axelsson, T ^a   Tobin, G ^a   Rosenquist, R ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN BCL 2; RNA;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; SURVIVAL RATE;

EID: 39349089293     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2405042     Document Type: Article

References (35)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804-815.
2. Delmer A, Ajchenbaum-Cymbalista F, Tang R, Ramond S, Faussat AM, Marie JP et al. Over-expression of cyclin D1 in chronic B-cell malignancies with abnormality of chromosome 11q13. Br J Haematol 1995; 89: 798-804.
3. Obermann EC, Went P, Tzankov A, Pileri SA, Hofstaedter F, Marienhagen J et al. Cell cycle phase distribution analysis in chronic lymphocytic leukaemia: A significant number of cells reside in early G1-phase. J Clin Pathol 2007; 60: 794-797.
4. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-234.
5. Binet JL, Lepoprier M, Dighiero G, Charron D, D'Athis P, Vaugier G et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 1977; 40: 855-864.
6. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
7. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-1847.
8. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-1854.
9. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101: 4944-4951.
10. Moshynska O, Sankaran K, Saxena A. Molecular detection of the G(-248)A BAX promoter nucleotide change in B cell chronic lymphocytic leukaemia. Mol Pathol 2003; 56: 205-209.
11. Skogsberg S, Tobin G, Krober A, Kienle D, Thunberg U, Aleskog A et al The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia. Leukemia 2006; 20: 77-81.
12. Thunberg U, Tobin G, Johnson A, Soderberg O, Padyukov L, Hultdin M et al. Polymorphism in the P2X7 receptor gene and survival in chronic lymphocytic leukaemia. Lancet 2002; 360: 1935-1939.
13. Starczynski J, Pepper C, Pratt G, Hooper L, Thomas A, Hoy T et al. The P2X7 receptor gene polymorphism 150 A→+C has no effect on clinical prognostic markers, in vitro sensitivity to fludarabine, Bcl-2 family protein expression or survival in B-cell chronic lymphocytic leukaemia. Br J Haematol 2003; 123: 66-71.
14. Frey UH, Nuckel H, Sellmann L, Siemer D, Kuppers R, Durig J et al. The GNAS1 T393C polymorphism is associated with disease progression and survival in chronic lymphocytic leukemia. Clin Cancer Res 2006; 12: 5686-5692.
15. Kaderi MA, Murray F, Jansson M, Merup M, Karlsson K, Roos G et al. The GNAS1 T393C polymorphism and lack of clinical prognostic value in chronic lymphocytic leukemia. Leukemia Res 2007, doi:10.1016/ j.leukres.2007.10.003.
16. Moshynska O, Sankaran K, Pahwa P, Saxena A. Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia. J Natl Cancer Inst 2004; 96: 673-682.
17. Tobin G, Skogsberg A, Thunberg U, Laurell A, Aleskog A, Merup M et al Mcl-1 gene promoter insertions do not correlate with disease outcome, stage or VH gene mutation status in chronic lymphocytic leukaemia. Leukemia 2005; 19: 871-873.
18. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994; 124: 1-6.
19. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 1997; 3: 614-620.
20. Schena M, Larsson LG, Gottardi D, Gaidano G, Carlsson M, Nilsson K et al. Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood 1992; 79: 2981-2989.
21. Faderl S, Keating MJ, Do KA, Liang SY, Kantarjian HM, O'Brien S et al Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia 2002; 16: 1045-1052.
22. Aguilar-Santelises M, Rottenberg ME, Lewin N, Mellstedt H, Jondal M. Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int J Cancer 1996; 69: 114-119.
23. Seto M, Jaeger U, Hockett RD, Graninger W, Bennett S, Goldman P et al Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J 1988; 7: 123-131.
24. Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 1985; 229: 1390-1393.
25. Young RL, Korsmeyer SJ. A negative regulatory element in the bcl-2 5′-untranslated region inhibits expression from an upstream promoter. Mol Cell Biol 1993; 13: 3686-3697.
26. Nuckel H, Frey UH, Bau M, Sellmann L, Stanelle J, Durig J et al. Association of a novel regulatory polymorphism (-938C→A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood 2007; 109: 290-297.
27. Jaffe E, Harris N, Stein H, Vardiman J (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001.
28. Chen X, Kwok PY. Homogeneous genotyping assays for single nucleotide polymorphisms with fluorescence resonance energy transfer detection. Genet Anal 1999; 14: 157-163.
29. Tobin G, Thunberg U, Johnson A, Eriksson I, Soderberg O, Karlsson K et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood 2003; 101: 4952-4957.
30. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257-2317.
31. Thunberg U, Johnson A, Roos G, Thorn I, Tobin G, Sallstrom J et al CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. Blood 2001; 97 1892-1894.
32. Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, Stevenson FK et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002; 99: 1023-1029.
33. Durig J, Naschar M, Schmucker U, Renzing-Kohler K, Holter T, Huttmann A et al. CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia 2002, 16: 30-35.
34. Hayat A, O'Brien, D, O'Rourke P, McGuckin S, Fitzgerald T, Conneally E et al. CD38 expression level and pattern of expression remains a reliable and robust marker of progressive disease in chronic lymphocytic leukemia. Leuk Lymphoma 2006; 47: 2371-2579.
35. Park BL, Kim LH, Cheong HS, Cho HY, Kim EM, Shin HD et al. Identification of variants in cyclin D1 (CCND1) and B-Cell CLL/ lymphoma-2 (BCL2). J Hum Genet 2004; 49: 449-454.